In patients with myocardial infarction (MI)-induced heart failure, angiotensin-converting enzyme (ACE) inhibitors are proven effective therapy in inhibiting the progression towards overt heart failure. However, the prognosis in these patients is still very poor, and optimisation of therapy is warranted. The antihypertensive and renoprotective effects of ACE inhibitors (ACE-Is) can be substantially enhanced by dietary sodium restriction. In line with the latter, the aim of the present study was to explore whether dietary sodium restriction enhances the efficacy of ACE-I after MI.
Introduction
Chronic activation of the renin-angiotensin-aldosterone system (RAAS) is regarded as one of the major causes of progressive deterioration of left ventricular (LV) function after acute myocardial infarction (MI). Accordingly, RAAS inhibition with angiotensin-converting enzyme (ACE) inhibitor therapy is associated with better cardiac function, 1 improved prognosis, 2 and increased quality of life. 3 Although ACE inhibition slows the gradual progression of myocardial dysfunction towards established chronic heart failure (CHF), it does not prevent it. [4] [5] [6] Hence, morbidity and mortality remain high, and further optimisation of therapy is warranted. One area which has hardly been explored is optimisation of ACE-I efficacy by dietary sodium restriction. Dietary sodium restriction has been shown to increase the antihypertensive and renoprotective efficacy of ACE-I treatment. [7] [8] [9] [10] Conversely, sodium loading may completely annihilate the effect of ACE-Is. 11 Considering that dietary sodium restriction is quite commonly advised to post-MI patients with LV dysfunction to reduce fluid retention, surprisingly little has been published about its effect on the efficacy of ACE-I therapy in these patients.The aim of the present study, therefore, was to explore the influence of dietary sodium restriction on the therapeutic effects of ACE-I treatment in rats with MI-induced LV dysfunction. The effects of 10 weeks' ACE-I treatment, with and without dietary sodium restriction, on blood pressure (BP) and cardiac hypertrophy, as well as ACE activity in plasma, and renal and cardiac tissue were evaluated.
Methods

Experimental protocol
Male Wistar rats (Harlan, Zeist, The Netherlands) were subjected to experimental MI by coronary ligation, or were sham operated (t=0).Two weeks after MI-induction (t=2), rats were maintained on 
Myocardial infarction
Rats were anaesthetised with isoflurane (2.0-2.5%) in a mixture of N 2 O and O 2 (2:1), intubated and mechanically ventilated. Coronary artery ligation was performed as described in detail elsewhere. 12 Briefly, a left-sided thoracotomy was performed and the left anterior descending coronary artery was occluded with a 6-0 silk suture, 1-2 mm from its origin. In sham-operated animals, the suture was placed but not tightened. Subsequently, the thorax was closed and rats were extubated upon spontaneous respiration. The coronary occlusion procedure results in extensive transmural MI, comprising a major part of the LV free wall. 13 Infarct size was determined by planimetry at mid-ventricular levels in transverse slices, as the percentage of LV circumference. 14 Rats with infarctions of less than 20% of the LV tissue were excluded from further analysis, since these infarcts are found to be haemodynamically fully compensated. 13, 15 Diet and medication Dietary sodium restriction was achieved by supplying the rats with food pellets containing 0.05% NaCl. Rats on a normal sodium diet were given food pellets with 0.3% NaCl. Zofenopril treatment was achieved by mixing the drug with rat chow during preparation (Hope Farms, Woerden, The Netherlands). Drug content and distribution in the rat chow were checked at the I.P.A.S. Institute (Ligornetto, Switzerland).Analysis of drug content of the food together with the assessment of food intake and body weight revealed that drug intake was similar (on average 5.5 and 5.3 mg/kg body weight/day) in both zofenopril groups.
Blood pressure measurements
After anaesthesia with isoflurane (2.0-2.5%), the right carotid artery was catheterised with a polyethylene catheter filled with 0.9% saline with heparin, 5000 U/L, connected to a pressure transducer (Statham 23 Db, Gould Instruments, Cleveland, OH). The catheter was advanced into the thoracic aorta and, after stabilisation, aortic BP was recorded.
In vitro left ventricular function
After 500 IU of heparin i.v., the heart was rapidly excised and arrested in ice-cold 0.9% NaCl. Retrograde perfusion of the aorta, essentially by the Langendorff method and as previously described, 12 was achieved immediately, using a modified Tyrode solution (composition in mmol/L: glucose 10, NaCl 128.3, KCl 4.7, NaHCO 3 20.2, CaCl 2 1.35, NaH 2 PO 4 0.42, MgCl 2 1.05, equilibrated with 95% O 2 and 5% CO 2 ). Perfusion pressure was maintained at 60 mmHg, and temperature was maintained at 37°C. After 10 minutes of stabilisation, LV pressure was measured by means of a catheter placed into the LV via the mitral valves and connected to a pressure transducer. Coronary flow was measured through a microprocessor, which controlled the perfusion pressure by adjusting the peristaltic perfusion pump. LV pressure, rate of contraction (+dP/dt), rate of relaxation (-dP/dt) and heart rate were measured and stored in a computerised database system.
ACE activity
ACE activity in plasma, LV (non-infarcted free wall) and kidney were determined using a method previously described in detail. 16 In short, tissues were homogenised in a 50 mmol/L K 2 PO 4 buffer at pH 7.5. Of the homogenates, 100 µl was pipetted in a 0.5 mol/L K 2 PO 4 buffer. Then the ACE substrate, Hippuryl-His-Leu (12.5 nmol/L, Sigma), was added and incubated at 37°C for exactly 10 minutes.The conversion of the substrate was stopped by adding 1.45 ml of 280 mmol/L NaOH. Thereafter, 100 µl of 1% phthaldialdehyde was added for the labelling of free His-Leu product. The amount of labelled His-Leu was fluorimetrically determined at excitation and emission wavelengths of 364 and 486 nm, respectively. Control samples were included, in which the conversion of substrate was prevented by adding NaOH before the substrate Hippuryl-His-Leu. Moreover, the substrate was added after the incubation period in these control samples.
Data analysis
Data are presented as mean+S.E.M. Untreated MIrats on normal sodium were compared to sham control rats using student's unpaired t-test, to study the effect of CHF after experimental MI. Subsequently, all groups were compared with each other using one-way analysis of variance (ANOVA), in combination with least significant difference post-hoc analysis for multiple comparisons (SPSS for Windows Standard version 10.0). Differences were considered statistically significant at a level of p<0.05 (two-tailed).
Results
General characteristics
Acute mortality after MI-induction was 26%; none of the sham-operated animals died. After post-hoc exclusion of rats with infarcts smaller than 20% from further analysis (15 out of 59), infarct sizes were evenly balanced between the MI groups (Table 1) . Body weights (BW) were comparable at the start of the protocol, but significantly lower at the end of treatment period in the groups receiving zofenopril.
Blood pressure
Mean arterial BP was lower after MI (73+4 mmHg), compared with sham control rats (87+4 mmHg, Table 2 ). Dietary sodium restriction per se did not affect BP (71+4 mmHg, p=NS versus untreated MI). Zofenopril treatment significantly reduced BP, independent of sodium diet; 44+3 and 48+3 mmHg for zofenopril + normal sodium and zofenopril + low sodium, respectively (both p<0.05 versus untreated MI).
In vitro left ventricular function
In isolated perfused Langendorff hearts, MIinduced LV dysfunction is substantiated by a reduction in LV systolic pressure and rate of contraction and relaxation, at similar coronary flow (see table 2 ). Neither zofenopril, nor low sodium diet, nor the combination, significantly affected in vitro LV function.
Cardiac hypertrophy
MI-induced hypertrophy was indicated by a marked increase in total heart weight, which could be attributed to increases in LV as well as right ventricular (RV) weight (see table 1 ). Zofenopril treatment, but not low sodium diet, prevented this cardiac response. However, when zofenopril treatment was combined with a low sodium diet, LV weight (LVW) was reduced by an additional 21% (p=0.05 ZOF-LS versus ZOF). RV weight underwent the same effect (20%), though statistical significance was not reached. When LV hypertrophy, represented by LVW:BW ratio, of MIrats was compared to sham-operated animals, all groups except the low sodium-zofenopril group showed a significant increase. LVW:BW ratio was only significantly lower in zofenopril + low sodium rats than in untreated MI rats, suggesting that LV hypertrophy induced by MI was only PAPER effectively prevented by the combination of zofenopril and sodium restriction (Figure 1 ).
ACE activity
Induction of LV dysfunction did not result in significantly elevated ACE activity in plasma and tissue ( Figure 2 ). However, plasma ACE activity was almost completely inhibited by zofenopril, irrespective of sodium intake. Although absolute values were much higher, a similar pattern was seen in the kidneys: i.e. marked inhibition by zofenopril but no additional effects by sodium intake. Interestingly, ACE activity in LV tissue was not reduced by zofenopril in rats that were fed on a normal sodium diet. Only in combination with a low sodium diet, was ACE activity significantly decreased. ACE activity in RV tissue showed an identical pattern (data not shown). LV ACE activity and LVW:BW ratio showed a significant correlation ( Figure 3 ).
Discussion
We studied the effect of dietary sodium restriction on the efficacy of ACE-I therapy after experimental MI in rats.The most important observations were: 1) LV ACE activity was inhibited only when zofenopril treatment was combined with dietary sodium restriction; 2) this effect occurred in heart, but not in plasma or in kidney tissue; 3) the significant reduction of LV ACE activity during combined ACE-I/low sodium diet treatment could be associated with a significant reduction in LVW:BW ratio, indicating prevention of hypertrophy; 4) A low sodium diet per se had no effects on any of the measured parameters.
ACE activity
In the present study, MI did not increase ACE activi-ty in plasma, nor in renal or LV tissue. Cardiac ACE may be activated in the early stage after induction of heart failure and is related to the degree of LV dysfunction. 12 Moreover, LV ACE activity appears also related to MI size. 17 The relatively moderate MI PAPER size in the present study may therefore not have increased ACE activity. Moreover, the major area in which ACE activity is elevated post-MI is the infarcted area itself, where mainly fibroblasts display increased activity, 18, 19 whereas analysis in the present study was restricted to the viable part of the LV free wall.
In accordance with the lack of activation after MI, there was no significant inhibition of LV ACE activity after zofenopril treatment. In previous studies, zofenopril significantly inhibited cardiac ACE activity, 20 but in the current study, the dose applied turned out to be lower. This confirms the importance of optimal dosing, as has been reported previously. 21 Dietary sodium restriction alone did not show any effect on the parameters measured in the present study.This is in general accordance with a previous study of Hodsman and co-workers in rats with MI. 22 The lack of effect of dietary sodium restriction alone on ACE activity in the present study suggests absence of a direct influence of sodium restriction on ACE activity and/or expression. However, other components of the RAAS may have been affected. In this respect, it is interesting to mention that both ACE gene expression, 23 and angiotensin II (Ang II) type 1 (AT 1 )-receptor expression may be regulated by sodium intake. [24] [25] [26] The AT 1 -receptor is regarded as the primary mediator of Ang II-induced cardiac remodelling. 27, 28 Although not affecting ACE activity when applied alone, when dietary sodium restriction was added to the zofenopril treatment, LV ACE activity was significantly reduced. Notably, this effect was specific for the LV, since no additional ACE inhibition was observed in plasma or kidneys. The lack of effects on renal ACE activity may seem paradoxical, since renoprotective effects of ACE inhibition were reported to be enhanced by dietary sodium restriction. 7, 8 However, this improved renoprotection, as measured by proteinuria reduction, 9 has not yet been shown to be associated with a further decrease in renal ACE activity. Furthermore, an effect of sodium restriction on tissue ACE activity may be confined to a situation of tissue damage, i.e. when the tissue RAAS is activated. Thus, the exact mechanisms underlying the additional cardio-or renoprotective effects of combined dietary sodium restriction and ACE-I treatment are not yet clear and requires further investigation.
Left ventricular hypertrophy
LVW was significantly increased after MI, and neither dietary sodium restriction, nor zofenopril treatment alone, had any effect. Only when the two treatments were combined was LV hypertrophy effectively prevented. Interestingly, the effects of therapy on LV ACE activity paralleled the effects on LV hypertrophy. Indeed, regression analysis revealed that LV ACE activity in zofenopril-treated rats was linearly related to LVW (see figure 3 ), suggesting that LV ACE activity is a major determinant of LV hypertrophy in the presence of an ACE-I. A previous study, using a three-times higher dose of zofenopril, which significantly decreased LV ACE activity as well as LV weight, 20 supports this suggestion. In contrast, a high sodium diet abolished the effect of perindopril on BP and cardiac hypertrophy, but cardiac ACE inhibition was found to be unaltered. 29 Although, in the latter study, BP rather than cardiac ACE activity was regarded as the determinant of cardiac hypertrophy, in the present study, the effects on hypertrophy were found to be independent of BP, i.e. BP was similarly reduced in the zofenopril groups without any additional effects of dietary sodium. It has been reported before that RAAS activation, rather than BP, determines cardiac hypertrophy after MI. 30 Cardiac function LV dysfunction was manifested by a lower LV developed pressure, rate of contraction and rate of relaxation, measured in vitro in isolated perfused hearts. None of the therapies affected this reduced LV function.Thus, the reported additional effect of sodium restriction on ACE activity and hypertrophy in the LV is not associated with effects on in vitro LV function. For that matter, previous studies have repeatedly shown the lack of effect of ACE-I treatment on in vitro LV function in infarcted rats for different ACE-Is, 31, 32 though in vivo the effects nevertheless are usually clearly positive in rats 15 as well as in patients. 33, 34 Clinical implications Dietary sodium restriction is commonly recommended and/or applied to heart failure patients, who are most often on ACE-I therapy as well. Theoretically, this dietary sodium restriction may have a dual effect. On the one hand it may (further) stimulate the RAAS, with its well-known deleterious effects. On the other hand, it may improve efficacy of inhibition of the RAAS, either by similar or by different mechanisms. In a recent study, this dual effect was illustrated by improved survival, but at the same time substantial potentiation of plasma renin activity, in spontaneously hypertensive rats with MI, treated with frusemide in addition to ramipril. 17 Frusemide, by inducing sodium depletion and increasing plasma renin activity, is considered to have similar effects on the sodium balance as dietary sodium restriction.
Nevertheless, data from the present study suggest that dietary sodium restriction may be safely applied to MI patients on ACE-Is, in that it specifically potentiates cardiac ACE inhibition, leading to further inhibition of cardiac remodelling, and without adverse side-effects such as hypotension. Whether dietary sodium restriction will lead to further improvement of cardiac function and/or prognosis when added to ACE-I treatment in patients with MI-induced heart failure, needs further investigation.
Conclusions
The present study aimed to explore whether dietary sodium restriction would influence the effects of ACE-I therapy with zofenopril in rats with MI. Results show that LV, but not plasma or renal ACE 
